Technical Trends Show Signs of Stabilisation
The primary catalyst for the rating upgrade was a notable change in the technical grade, which moved from bearish to mildly bearish. While the weekly Moving Average Convergence Divergence (MACD) remains bearish, the monthly MACD has improved to mildly bearish, indicating a potential easing of downward momentum. The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, suggesting a neutral stance in momentum.
Bollinger Bands present a mixed picture: weekly readings are bullish, signalling short-term price strength, whereas monthly bands remain mildly bearish, reflecting longer-term caution. The daily moving averages continue to be mildly bearish, but the weekly Know Sure Thing (KST) indicator has turned mildly bullish, hinting at emerging positive momentum. Dow Theory assessments align with this, showing mild bullishness on a weekly basis but mild bearishness monthly. On Balance Volume (OBV) remains mildly bearish across weekly and monthly timeframes, indicating volume trends have yet to fully confirm a sustained uptrend.
These technical nuances suggest that while the stock is not yet in a strong uptrend, the downtrend is losing intensity, justifying a more neutral Hold rating rather than a Sell.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Valuation Metrics Indicate Attractive Pricing
Raaj Medisafe’s valuation has improved significantly, contributing to the upgrade. The company currently trades at an enterprise value to capital employed (EV/CE) ratio of 1.9, which is considered very attractive relative to its peers in the packaging and medical equipment sectors. This valuation discount is notable given the company’s robust return on capital employed (ROCE) of 11.1%, which signals efficient use of capital to generate profits.
Despite the stock’s underperformance over the past year, with a return of -5.71% compared to the BSE500’s 5.35% gain, the company’s profits have surged by 115.1% during the same period. This disconnect is reflected in a low price/earnings to growth (PEG) ratio of 0.1, suggesting the stock is undervalued relative to its earnings growth potential. The 52-week price range of ₹63.56 to ₹102.35 places the current price of ₹77.18 closer to the lower end, reinforcing the case for valuation support.
Financial Trends Demonstrate Strong Growth Momentum
Raaj Medisafe’s financial performance over recent quarters has been a key factor in the rating revision. The company has reported positive results for three consecutive quarters, with net sales for the nine months ending December 2025 reaching ₹58.63 crores, reflecting an annual growth rate of 64.38%. Operating profit has also expanded robustly at 60.53% annually, underscoring operational efficiency improvements.
Profit after tax (PAT) for the nine-month period stands at ₹6.67 crores, marking an impressive growth of 152.65%. The company’s debtor turnover ratio has improved to 7.11 times, indicating enhanced collection efficiency and working capital management. These financial trends highlight a healthy growth trajectory, although the company’s high average debt-to-equity ratio of 3.93 times remains a risk factor that investors should monitor closely.
Quality Assessment Reflects Mixed Signals
Raaj Medisafe’s overall quality grade remains moderate, with a Mojo Score of 51.0 and a Mojo Grade of Hold, upgraded from Sell. The company’s market capitalisation grade is 4, reflecting its mid-cap status within the packaging sector. Promoters continue to hold a majority stake, which can be a positive governance signal, but the high leverage ratio tempers the quality outlook.
Long-term returns have been impressive, with a 10-year return of 885.70% vastly outperforming the Sensex’s 227.83% over the same period. Similarly, five-year and three-year returns stand at 634.35% and 140.81%, respectively, well above benchmark indices. However, the recent one-year underperformance and elevated debt levels suggest that the company is navigating a transitional phase.
Stock Price and Market Context
The stock closed at ₹77.18 on 5 January 2026, up 4.99% from the previous close of ₹73.51. Intraday trading ranged between ₹73.99 and ₹77.18, reflecting increased buying interest. Despite the recent price appreciation, the stock remains below its 52-week high of ₹102.35, indicating room for further recovery if positive trends persist.
Comparatively, Raaj Medisafe has outperformed the Sensex in shorter timeframes, with one-week and one-month returns of 13.50% and 12.28%, respectively, versus the Sensex’s 0.85% and 0.73%. Year-to-date returns also favour the stock at 10.24% against the Sensex’s 0.64%. These short-term gains align with the improved technical outlook and growing investor confidence.
Holding Raaj Medisafe India Ltd from Packaging? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Outlook and Investor Considerations
While the upgrade to Hold reflects a more balanced view of Raaj Medisafe’s prospects, investors should weigh the company’s strong growth and attractive valuation against its elevated debt levels and mixed technical signals. The improving technical indicators suggest a potential stabilisation in price trends, but the mildly bearish monthly signals counsel caution.
Financially, the company’s rapid sales and profit growth, coupled with efficient working capital management, provide a solid foundation for future performance. However, the high debt-to-equity ratio of nearly 4 times remains a concern, particularly in a rising interest rate environment or if operational challenges arise.
Long-term investors may find value in the stock’s discounted valuation and strong historical returns, but should monitor quarterly results and leverage metrics closely. The current Hold rating implies that while the stock is no longer a sell, it may not yet warrant a Buy recommendation until technical and financial trends further improve.
Summary
Raaj Medisafe India Ltd’s investment rating upgrade from Sell to Hold is driven by a combination of improved technical trends, attractive valuation metrics, robust financial growth, and a moderate quality assessment. The company’s recent quarterly results and long-term performance underpin this more positive outlook, although elevated debt and mixed technical signals suggest a cautious stance remains prudent. Investors should continue to monitor developments closely as the stock navigates this transitional phase.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
